For the past 50 years, the principle of the 3Rs (replacement, reduction and refinement) has effectively reduced the use of animals in preclinical studies.
Though some complex alternatives are available to support efficacy and safety assessment, in vivo studies are still necessary to translate the science from bench to man.
Continued enhancements of validated in vivo models targeting respiratory diseases are incorporating more clinically relevant biomarker and functional endpoints to maximize the outcomes from each animal.
This White Paper Includes:
- Understand how the 3Rs are improving in vivo model outcomes
- Learn how market trends are impacting Big Pharma
- Discover areas of new in vivo developments
- Explore how including multiplex, clinically relevant endpoints improve effectiveness of studies
Click here to view the White Paper
Click here for more information on Envigo